TD Cowen Issues Positive Forecast for Quanterix (NASDAQ:QTRX) Stock Price

Quanterix (NASDAQ:QTRX) had its target price upped by TD Cowen from $13.50 to $16.00 in a report released on Wednesday morning,Benzinga reports. The firm currently has a hold rating on the stock.

Separately, Scotiabank dropped their price objective on Quanterix from $32.00 to $28.00 and set a “sector outperform” rating for the company in a research note on Monday, August 12th.

Quanterix Price Performance

Quanterix stock opened at $12.40 on Wednesday. The stock has a fifty day moving average price of $12.97 and a two-hundred day moving average price of $14.01. Quanterix has a 52-week low of $10.50 and a 52-week high of $29.70. The firm has a market capitalization of $475.90 million, a P/E ratio of -11.81 and a beta of 1.36.

Insider Transactions at Quanterix

In other Quanterix news, Director David R. Walt bought 47,000 shares of the firm’s stock in a transaction dated Tuesday, August 20th. The shares were bought at an average price of $13.29 per share, for a total transaction of $624,630.00. Following the completion of the acquisition, the director now owns 1,487,342 shares of the company’s stock, valued at approximately $19,766,775.18. This trade represents a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. Company insiders own 6.90% of the company’s stock.

Institutional Trading of Quanterix

Large investors have recently made changes to their positions in the business. Lord Abbett & CO. LLC grew its holdings in shares of Quanterix by 22.9% during the first quarter. Lord Abbett & CO. LLC now owns 1,757,153 shares of the company’s stock worth $41,398,000 after purchasing an additional 326,876 shares during the last quarter. Harbor Capital Advisors Inc. boosted its holdings in Quanterix by 772.3% in the second quarter. Harbor Capital Advisors Inc. now owns 83,941 shares of the company’s stock valued at $1,109,000 after acquiring an additional 74,318 shares during the last quarter. Emerald Advisers LLC boosted its holdings in Quanterix by 5.6% in the third quarter. Emerald Advisers LLC now owns 719,217 shares of the company’s stock valued at $9,321,000 after acquiring an additional 38,230 shares during the last quarter. Easterly Investment Partners LLC boosted its holdings in Quanterix by 779.9% in the second quarter. Easterly Investment Partners LLC now owns 692,746 shares of the company’s stock valued at $9,151,000 after acquiring an additional 614,012 shares during the last quarter. Finally, Assenagon Asset Management S.A. bought a new position in Quanterix in the second quarter valued at about $3,389,000. Institutional investors own 86.48% of the company’s stock.

About Quanterix

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications.